Neoadjuvant Uveal Melanoma Monotherapy Darovasertib Granted Breakthrough Drug Status
Time to read:01:09. The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for darovasertib, a first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) recommended for enucleation
Source: PR Releases
Feature
Text
Uveitis Advancements: Priovant Therapeutics Secures FDA Fast Track for Brepocitinib and Begins Phase 3 Study
Time to read: 01:08
Source: PR Wire
Text
Promising Results for AGTC-501 in Treating XLRP: 24-Month Data from SKYLINE Trial
Time to read: 01:05. presentation of 24-month interim safety and efficacy results of the Phase 2 SKYLINE trial in patients with XLRP at the American Academy of Ophthalmology’s Annual Meeting in Chicago, Illinois.
Source: PR NewsWire
Text
Phase 111 GATHER 2 Clinical Trial shows Astellas' IZERVAY™ reduces GA lesion growth
Astellas Pharma Inc. announced results from the GATHER2 Phase 3 clinical trial for IZERVAY™ (avacincaptad pegol intravitreal solution), showing continued reduction in geographic atrophy (GA) lesion growth in patients with age-related macular degeneration (AMD) over two years. Key findings include
Source: Astellas Press Release
Text
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Chronic retinal conditions, AMD, wetAMD, nAMD, diabetic retinopathy, gene therapy, anti VEGF therapy
Source: REGENXBIO Inc
Text
